Placeholder Image

字幕列表 影片播放

  • The following content is provided under a Creative

  • Commons license.

  • Your support will help MIT OpenCourseWare

  • continue to offer high-quality educational resources for free.

  • To make a donation or view additional materials

  • from hundreds of MIT courses, visit MIT Open CourseWare

  • at ocw.mit.edu.

  • JOANNE STUBBE: We talked last time

  • about kinetics, steady-state kinetics,

  • pre-steady-state kinetics, how you design the experiments,

  • what kinds of information you can get out

  • of each experimental design.

  • And we introduced all of that material.

  • And today, what I want to do is come back to the model.

  • You saw it at the very beginning,

  • and you've seen it in a lecture.

  • And specifically, where did this model come from?

  • That's what we're going to focus on.

  • OK, and so in order to be able to understand this model,

  • you have to design assays.

  • And you're going to see over and over again

  • over the course of the semester figuring out

  • how to design an assay, in this case, isn't so hard,

  • but in many cases is really tough.

  • And that's the key to being able to get kinetic information

  • is designing the assay.

  • So if you look here, today, we're

  • going to be looking at GTP is hydrolyzed.

  • So you need to think about, as a chemist, how

  • you could study that reaction.

  • How would you look at starting material?

  • How would you look at product as a function

  • of time, which is what we were talking about last time?

  • And we're going to talk about that first.

  • We're going to talk about use of radioisotopes first.

  • And we've already been talking about radioisotopes in class

  • the last couple of lectures.

  • So we decided to focus most of our energy

  • now on radioisotopes.

  • And then the second kind of probe you're going to see

  • is a fluorescent probe.

  • We're going to use fluorescent probes over and over again.

  • And the details of the fluorescent probes

  • and how they work isn't going to come

  • in until the last recitation, which is recitation 13.

  • So from the point of view of thinking

  • about Rodnina's paper, what you need

  • to think about is, if you have a probe,

  • and you stick it in a different environment, it changes.

  • And you can watch it change, OK, without looking at the details.

  • But that's something you do need to think about,

  • but we're not going to talk about that.

  • OK, so we have a way of monitoring potentially GTPase.

  • And we'll talk about that today.

  • What other reaction can we monitor in here?

  • We can monitor formation of the polypeptide chain.

  • And so that's the other thing.

  • And both of these chemical transformations

  • use radioactivity.

  • OK, so that's where we're going to focus on it initially.

  • And then hopefully-- how many of you

  • went back and reread the paper for this week from last week?

  • Did any of you go back and reread it?

  • OK, so I think it's good.

  • I just think, you know, every time I read a paper--

  • I read a paper.

  • Sometimes, I've read it 10, 15 times over the course

  • of my career.

  • And as I learn more and think about things differently,

  • I keep seeing new things.

  • And this paper is just packed full of information.

  • So I could say you could read it another 10 times,

  • and you'd still keep learning stuff out of reading it.

  • And in the very beginning, that's

  • what we're trying to teach you to do.

  • What do you look at in the paper to learn

  • how to critically evaluate what's

  • being presented in the model, which

  • is maybe what you're going to build your research program on?

  • Somebody else's data, is it correct?

  • Is it not correct?

  • OK, so we're going to use radioactivity.

  • I'm going to start there.

  • And then to look at these first few steps,

  • which are binding steps, that's where

  • we're going to look at the fluorescent probe.

  • And there were three different kinds

  • of experiments that were described in this paper--

  • looking at the rates of the reactions as a function

  • of the concentration of the ribosome--

  • you need to think about why they looked at a concentration

  • dependence--

  • measuring fluorescence changes, and then they

  • used non-hydrolyzable GTP analog.

  • Why did they use that?

  • Do you remember what the non-hydrolyzable GDP

  • analog was?

  • So where's the n?

  • AUDIENCE: It's between beta and gamma.

  • JOANNE STUBBE: So it's non-hydrolyzable.

  • It is hydrolyzable, but not under

  • the experimental conditions.

  • So what does it do?

  • Why would you want to use something

  • like that to get information about the first few steps?

  • AUDIENCE: It's along the reaction continuum.

  • JOANNE STUBBE: Yeah, so you don't

  • let the reaction continue.

  • So what that does, if it's working correctly,

  • is it puts a block here.

  • And then you can potentially monitor what's going on here.

  • And from the data that you looked at,

  • it's not really so clear what was going on there

  • unless you went back and read the preceding paper.

  • So there had been a decade worth of experiments on this system

  • before this paper came out summarizing

  • the conclusions about what they are thinking about fidelity.

  • OK, so what we're going to do is talk about radioactivity.

  • And our objective is simply-- and we'll come back to this

  • at the very end--

  • is to use all this experimental data, the concentration

  • dependence, the radioactive isotope experiments,

  • the stop flow fluorescence experiments,

  • and try to come up with a model that

  • can explain all of the data.

  • OK, so you make some measurement.

  • What you're measuring is some k apparent.

  • And that's usually a first-order rate constant

  • because it's happening on the enzyme.

  • OK, so you measure these numbers.

  • Well, what do they mean?

  • You don't know what they mean.

  • And why don't you know what they mean?

  • Because the kinetic mechanism is so complicated.

  • You saw that with the steady-state analysis

  • of km and kcat last time.

  • So in the end, though, if you come up with a model,

  • and it can explain all the data because you've

  • done many, many experiments, it can

  • be quite informative about the question we're

  • focused on is specificity.

  • How do you distinguish between phenylalanine and leucine

  • and proofreading?

  • How do you decide whether you're going

  • to form the right peptide bond or the incorrectly charged tRNA

  • is going to dissociate?

  • OK, so that's what you want to come out with.

  • You want to look at the ratio of these rate constants

  • and the ratio k3 to k minus 2.

  • And when you look at the experimental data, which we'll

  • look at the end today, it should make sense to you

  • in terms of this model.

  • OK, but let's put it this way.

  • In most cases, you don't come out with a unique model.

  • It's a working hypothesis that people for the next 15 years,

  • if it's an interesting problem, will take pot shots at

  • to try to understand in more detail what's really going on.

  • OK, so what I want to do is talk about two methods,

  • but the focus probably won't get very far

  • in terms of the second one.

  • But today, we're going to look at radioisotopes and how

  • you use that to do the assay for GDP hydrolysis

  • and peptide bond formation.

  • OK, so what is an isotope?

  • OK, so how many of you guys have actually

  • worked with radioisotopes?

  • Any of you?

  • No, OK, so you know, maybe they don't use this anymore.

  • Biochemists for the decades have used isotopes.

  • Every paper I read has isotopes in it.

  • But you know, I'm old school.

  • So maybe people don't use it.

  • But I think the power of it is its sensitivity.

  • I'm going to show you that today.

  • And the other power of it is that you

  • have no perturbation of your system

  • and there are almost no probes like that.

  • You're sticking on green fluorescent protein.

  • Well, what does it do to the whole rest of the protein?

  • You have to perturb to see, but radioisotopes

  • have minimal perturbation.

  • So it's still a very important probe,

  • but it probably depends on what kinds of questions

  • you're focused on.

  • So what is an isotope?

  • So an isotope is atoms with the same number of protons

  • and a different number of neutrons.

  • That's called the mass number.

  • So what you have here for carbon,

  • which is one of the common isotopes you guys will be using

  • if you do any kind of biochemistry,

  • we have C-12, C-13, and C-14.

  • OK, and so this is the atomic number, which

  • is the number of protons.

  • OK, so the only difference between these guys

  • is a neutron or two neutrons.

  • OK, so there's minimal difference.

  • And so what are the isotopes that you see used in biology?

  • So we've already seen many of these in this paper,

  • but we've also talked about some of them in class today

  • and in the preceding class.

  • So we're going to be using over the course of the semester

  • isotopes of hydrogen. Why?

  • Because if you look at your metabolic pathways,

  • you're always cleaving carbon-hydrogen bonds.

  • OK, so this isotope becomes incredibly important.

  • C-12, C-13, anybody know where you use C-13?

  • AUDIENCE: In NMR.

  • JOANNE STUBBE: NMR, so if you're working for Mei Hong,

  • you might be doing isotopic labeling using C-13.

  • If you're doing any kind of metabolic label chasing,

  • you're going to see the radioisotope is, which is what

  • we're talking about, is C-14.

  • Working

  • So you see often, all the time, you see nitrogen and oxygen.

  • And oxygen has three isotopes.

  • Nitrogen has two.

  • None of them are radioactive.

  • OK, so you're never going to be using the methods

  • we're describing today.

  • But frequently, in NMR again, you

  • might replace N-14 with an N-15.

  • And today, we will see that we're

  • using isotopes of phosphorus.

  • What about phosphorus-31?

  • Where do you see that?

  • Have you thought about this?

  • Maybe you have, and maybe you haven't.

  • Phosphorus-31 versus phosphorus-32,

  • what's the normal abundance isotope of phosphorus?

  • 31, so phosphorus-31 has a nuclear spin of a 1/2.

  • So you frequently use that as well in NMR.

  • And P-32 is used--

  • it's radioactive and is used in today's experiments.

  • OK, so this is something that in the back of your mind

  • you should think about.

  • What are stable versus unstable isotopes?

  • And what we're talking about today is unstable isotopes.

  • So what I want to do is we're not

  • going to go into this in a lot of detail,

  • but I want to describe the things I think

  • you need to think about if you're ever going

  • to use radioactivity and how you make measurements,

  • quantitative measurements.

  • And so we're going to be looking at a radioisotope.

  • And what do we know about radioisotopes?

  • They're unstable.

  • OK, and depending on which atoms they are,

  • they have different stabilities.

  • And they decay spontaneously into some new configuration.

  • They have a nuclear decay spontaneously into a new state.

  • And during this process, during this decay,

  • they emit ionizing radiation.

  • They emit energy.

  • So during this process--

  • so this is the whole thing you need to remember.

  • They emit energy.

  • And the energy is in the form of ionizing radiation.

  • It could be alpha, beta, or gamma radiation.

  • And so what we're going to be looking for

  • is trying to detect that energy that's actually released.

  • OK, so before I go on, we've already

  • seen all of these isotopes used already

  • in class, even though we've only gone through seven lectures.

  • And when we look at the LDL receptor and cholesterol

  • homeostasis, there aren't very many LDL receptors.

  • You something highly sensitive, which is something

  • that you need to think about.

  • And I-125 which is a gamma emitter,

  • is what you end up using.

  • We'll come back to that in recitation,

  • I don't know, 8 I think it is.

  • OK, so they're unstable.

  • And they spontaneously decay into a new configuration.

  • And they release energy.

  • And what we want to do is detect the energy.

  • The ones that most of you will be focused on,

  • if you use radioactivity in your experiments,

  • will probably be all beta emitters.

  • And all of these guys over here are beta emitters.

  • And you've already seen all of these radioisotopes.

  • OK, so what do we know about these isotopes?

  • There's two things you need to think about.

  • So this is the properties.

  • And one of them is the energy of the beta particle or gamma

  • particle released.

  • And if you look over here, what do you see?

  • Tritium has 18.6 with this kind of unit.

  • The unit might not mean very much to you.

  • All I want you to do is look at the relative energies.

  • Versus phosphorus, 1,710, so it has much more energy released.

  • And what does that mean?

  • If you've never worked with radioactivity, you might not--

  • a lot of chemists are petrified of radioactivity.

  • I mean you could eat most tritium and C-14.

  • Don't tell anybody I said that.

  • But you could eat almost all tritium or C-14-labeled

  • molecules you end up buying.

  • They don't really do anything to you because the energy is low.

  • And if you wear plastic gloves or something,

  • that protects you from any kind of energy released.

  • P-32, on the other hand, which isn't used as frequently,

  • does anybody know where that used to be use all the time?

  • I've used tons of P-32 in my lifetime.

  • Where do you think that was used initially?

  • AUDIENCE: With DNA.

  • JOANNE STUBBE: In what?

  • AUDIENCE: DNA.

  • JOANNE STUBBE: DNA sequencing, yeah.

  • So DNA sequencing, which you guys don't do,

  • you send it out to have somebody do it for you.

  • We used to run these huge gels.

  • And we used to have to run many, many sequencing

  • gels to sequence something that was 500 base pairs long.

  • And P-32 was the method of detection.

  • So what you do there is it's still not that bad,

  • but you have to have a safety shield.

  • So if any of you use radioactivity at MIT,

  • they have radiation safety, and you go.

  • Even if there's somebody else in the lab using it,

  • and you're not, you should go just read the handouts

  • that they give you to be aware of what's

  • going on with radioactivity.

  • I would say the biggest issue is that, if somebody

  • spills it and doesn't clean it up,

  • then it can contaminate everybody's experiments

  • in the lab.

  • That I would say is one of the biggest

  • issues with radioactivity.

  • OK, so iodine, again, is a gamma emitter.

  • So that's in a category by itself.

  • So the other thing that I think people don't really

  • have very much feeling for is the half-life of decay.

  • And if you look at that, look at how many years for your C-14

  • to decay by 50% from whatever the number is, forever.

  • You don't have to worry about it.

  • You can sit it in your--

  • you can leave it in your refrigerator,

  • and it's good for your lifetime anyhow.

  • On the other hand, P-32, for example,

  • has a half-life of 14 days.

  • So what does that mean?

  • It's spontaneously decaying continuously.

  • And if you have it for 14 days, you start out with some number.

  • We'll define what that number is.

  • And then 14 days later, you only have half as much.

  • OK, so you need to know something about the half-life.

  • And the only one you need to ever think about

  • is P-32, which they needed to think

  • about in the experiments that are described in the Rodnina

  • paper.

  • So you have the energy released, and the energies are distinct.

  • And so the question then is what we really want to do

  • is think about quantitation.

  • So that's going to be the key thing

  • is we want to be able to quantitate radioactivity.

  • And to do that, we need a method of detection.

  • And there are a number of methods of detection.

  • The one that--

  • I guess, again, I'm not sure.

  • I think I'm the only one in the chemistry department

  • that has a way of detecting radioactivity

  • using an instrument called a scintillation counter.

  • So this is sort of a very oversimplified view

  • of what's going on in your scintillation counter.

  • And so people come from all-- actually,

  • they come from lots of places on campus to use it.

  • So again, I think that's common.

  • I don't know how many people are using radioactivity.

  • But you have radiolabeled molecule here.

  • It would be leucine.

  • And you have tritiated leucine.

  • OK, or it would be P-32-labelled GTP.

  • Those are the two molecules that are used in these experiments.

  • You put it into a little vessel with some kind of fluid.

  • And the fluid that you use, whether it's organic, water,

  • aqueous, or mixtures, depends on the molecules

  • you're dealing with.

  • OK, and the energy gets transferred in some way

  • to the solvent in your solution.

  • And then you put in a small molecule

  • called the scintillant, which can

  • remove the energy from the solvent

  • and absorb that energy in some way.

  • And again, it depends on-- the standard one

  • we use in my lab is POPOP.

  • You can look up scintillants in Google,

  • and you can find out what the structures of these things are.

  • And then these things decay.

  • And when they decay, the energy is

  • related to the detection method using a photomultiplier tube.

  • So it gives you a quantitative measure

  • of how much radioactivity you have over here

  • and how much you get out on this side.

  • Now, if you look at this process,

  • it's complicated because you have energy transfer.

  • So what can happen during this energy transfer

  • depending on the energy of your radioisotope?

  • Anybody got any ideas?

  • What might you have to worry about?

  • AUDIENCE: You're looking at efficient transfer.

  • JOANNE STUBBE: Yeah, so the efficiency of the transfer.

  • And if you have something in a solution,

  • often, you're doing crude cell extracts.

  • OK, so you have a lot of things in there

  • that can also absorb the energy.

  • So at any stage along the way, you can get quenching.

  • OK, and if you get quenching, that reduces the amount you

  • detect over here.

  • OK, so that's going to throw your numbers off.

  • So where is quenching a problem?

  • Quenching is a problem--

  • we just looked at all these energies.

  • OK, tritium has the lowest energy.

  • OK, P-32 has a much higher energy.

  • So if you look at it, and you have to figure this out

  • for every system you work on.

  • I've worked on tritium-labeled molecules

  • where you couldn't be quenched by 90%.

  • So if you have some measure-- we'll call it decompositions

  • per minute, 10,000-- if it's quenched by 90%,

  • you've lost a lot of your sensitivity.

  • So you have to figure out a way to determine whether you'll

  • get quenching or not.

  • Otherwise, your numbers are completely off.

  • So why do you want to quantitate your radioactivity?

  • Where would you be using radioactivity?

  • And why would this quenching make a difference?

  • Yeah?

  • AUDIENCE: This is just a question.

  • JOANNE STUBBE: Yeah, sure.

  • AUDIENCE: What's kind of like the nature

  • of the solvent to the fluorescence involved.

  • Is that like a [INAUDIBLE] kind of idea?

  • JOANNE STUBBE: So it's just some kind of energy transfer.

  • Yeah, so I mean it depends on what the molecules are.

  • An it depends on what the solvent is.

  • AUDIENCE: OK.

  • JOANNE STUBBE: OK, so every single one of these systems,

  • you need to go in and look at the details of what's going on.

  • And so when you do this, people have worked out

  • these conditions so that when you're measuring--

  • and so this is an important question you're asking.

  • How do you know that what you're measuring really

  • is related to what's way over here?

  • So that's the absolutely the right question to ask.

  • And so when you start, for example, the first thing you do

  • is every scintillation counter comes with a standard.

  • OK, and so the instrument is calibrated.

  • And if you care about radioactivity,

  • you have somebody come in, and they calibrate the instrument

  • twice a year.

  • OK, so all of this stuff is really important.

  • And the question of sensitivity is important.

  • We're going to see what you're measuring is something called

  • decompositions per minute.

  • OK, that's the readout you get from the instrument.

  • And so you might be getting 100,000 of these things.

  • But in fact, you might be getting five.

  • OK, is five real?

  • Five can be real if you count it so you

  • get a statistical distribution to make

  • sure the five is real, that it's not five plus or minus five.

  • OK, so radioactivity is incredibly sensitive.

  • And you can extend the sensitivity

  • by just counting your material in this instrument

  • for a very long period of time.

  • OK, so where would you want--

  • where have you already seen that you would use radioisotopes?

  • What did you see today in class, for example, in ribo-x?

  • You looked at an experiment with ribo-x today in class.

  • AUDIENCE: Oh, the cysteine incorporation.

  • JOANNE STUBBE: Yeah, with cysteine incorporation.

  • What were you looking at?

  • AUDIENCE: It limited the radioactive system.

  • JOANNE STUBBE: Right, but what we are using to look at this?

  • So we're talking about the detection method.

  • So I'm going to describe another detection method.

  • Would you be looking at this by scintillation counting?

  • No, so you need another method.

  • AUDIENCE: So like one of those phosphorimagers.

  • JOANNE STUBBE: Right, so I'm going to show you.

  • That's the next thing.

  • So what you could have, for example, is a TLC plate.

  • Or you could have--

  • they were using a gel, an agarose gel probably.

  • So you need a way of detect the radioactivity that's

  • going to be distinct from scintillation counters

  • where you use little vials and scintillation fluid.

  • And you have a completely different method of detection.

  • And these methods keep changing.

  • And so I don't update them anymore.

  • I'm not sure what the current technology is.

  • It's all secret anyhow.

  • So they tell you sort of something about what it is,

  • but they don't tell you any of the details

  • because it's all proprietary.

  • OK, so in that case, what were we looking at?

  • We were just looking for incorporation.

  • We were doing some labeling experiment in the cell.

  • OK, so we were chasing a label.

  • So that you're going to see a lot.

  • That's how all the metabolic pathways were figured out.

  • The advent of C-14 as an isotopic label

  • revolutionized our understanding of glycolysis, fatty

  • acid biosynthesis, et cetera.

  • And today, what are we using radioisotopes today to do?

  • We're using it to do what?

  • We're looking at GTP.

  • We want to look at GTP going to GDP plus Pi.

  • OK, so what are we using this for?

  • To get information for our model.

  • What do we do as a function of time?

  • Why do we want to use gamma P-32-labeled ATP?

  • And how do we use this in analysis?

  • Did you even know that we're using gamma P-32-labeled GDP?

  • How many knew that?

  • Anybody read that in the methods section?

  • You, over there, did you read that in the methods section?

  • What's your name?

  • AUDIENCE: Mathis.

  • JOANNE STUBBE: Matt?

  • AUDIENCE: Mathis.

  • JOANNE STUBBE: Matt, did you read that in the methods

  • section or not?

  • AUDIENCE: No.

  • JOANNE STUBBE: No, did anybody read it in the methods section?

  • So I mean that's what-- again, this

  • is what this recitation is all about

  • is looking at the details of what's going on.

  • And I think when you first start doing something like you don't

  • know what details to look for.

  • Some of you might have read it, but it didn't mean anything.

  • So it went in one ear and out the other.

  • Yeah?

  • AUDIENCE: Wouldn't you have to use gamma labeled GTP though?

  • I mean the hydrolysis gives you GDP and phosphate.

  • So that's the only--

  • I mean, if you labeled another one,

  • it doesn't give you as much information.

  • JOANNE STUBBE: OK, so if you labeled--

  • say you labeled the base.

  • So let's just call this base.

  • Say you put a tritium in the base, OK, versus--

  • hopefully, you all know this, but this is the gamma position

  • versus a label here.

  • Why are you putting the label here?

  • What's going on in this reaction?

  • Actually, this was interesting because this

  • is the second recitation where I don't think anybody understood

  • what was going on in this reaction, which

  • is rather disturbing.

  • What's going on in this reaction?

  • So we're going GTP.

  • So this is G. So you have a nucleoside

  • and three phosphates, TP.

  • And what are you producing out the other side?

  • GDP.

  • So what's happening during this reaction?

  • Yeah?

  • AUDIENCE: [INAUDIBLE]

  • JOANNE STUBBE: Yeah, so you're hydrolyzing it.

  • So in some way, that's what all of these GTPases are about.

  • You're going to see these GTPases not only

  • in translation.

  • You're going to see it in three of the sections

  • that I talk about.

  • GTPases are everywhere.

  • OK, so what you're looking at is then

  • some way you have hydrolysis of the gamma phosphate.

  • OK, so why are you labeling the gamma phosphate?

  • You could have labeled actually the alpha or the beta.

  • AUDIENCE: You wouldn't be watching the reacting.

  • JOANNE STUBBE: Yeah, you want to watch your reaction.

  • So if you have an isotope here, which

  • we're going to watch it using some method,

  • scintillation counting or phosphorimaging, and where

  • does the label end up?

  • The label ends up here.

  • OK, well, if you put the label in alpha or beta,

  • could you follow the reaction?

  • OK, well, you're shaking your head no.

  • Why couldn't you follow the reaction?

  • AUDIENCE: Because it would stick in the GDP [INAUDIBLE]----

  • JOANNE STUBBE: So it would be in GDP.

  • AUDIENCE: --there's no GTP in GDP.

  • JOANNE STUBBE: Yeah, is there a difference

  • chemically between GDP and GTP?

  • Again, this is what I'm finding.

  • You need to think about the structures of everything

  • you're working with.

  • We're chemists.

  • OK, what is the difference between the diphosphate

  • and the triphosphate?

  • AUDIENCE: It's harder to hydrolyze the next phosphate

  • off.

  • JOANNE STUBBE: Well, it's not.

  • You know, all of these things--

  • without an enzyme, all of these things are hard to hydrolyze.

  • Why?

  • Because you've got negative charges all over the place,

  • and a nucleophile can't get into the active site.

  • So they're all hard to hydrolyze.

  • So that's not-- you have to think about that,

  • but that's not what I'm looking for.

  • Yeah?

  • AUDIENCE: So if you run a gel or something,

  • they should come out--

  • GDP and GTP are going to come out in the same-ish area,

  • whereas, obviously, phosphate--

  • JOANNE STUBBE: OK, so that's what you need to think about.

  • But what can you take advantage of as a chemist where

  • they don't come out in the same-ish area?

  • AUDIENCE: I mean, if you label them,

  • the gamma phosphate, then the label

  • won't come out nearly anywhere.

  • JOANNE STUBBE: So that's absolutely true.

  • But what is it about this molecule?

  • Because I've been sloppy.

  • What is it about this molecule that

  • allows the distinction between your starting materials

  • and products?

  • This is what developing an assay is all about.

  • How are you going to monitor this reaction?

  • So in this paper, one of the graphs looked at Pi production.

  • We're going to look at this if we get this far.

  • OK, so how would you distinguish between these things

  • as a chemist?

  • You have no idea.

  • You, you haven't any idea, not good.

  • OK, what about you?

  • This isn't a hard question.

  • Look at the structures.

  • And as a chemist, how would you distinguish

  • your starting material from your products?

  • That's the question.

  • And that is the question in any assay you have to develop.

  • That's what you've got to figure out.

  • You've got to figure out a way to distinguish

  • the starting materials from the product.

  • Now, if we have a base here, and if this is G,

  • we have a base here.

  • What do we know about guanine?

  • What's its absorption look like?

  • What's its absorption spectrum look like?

  • AUDIENCE: 210 [INAUDIBLE].

  • JOANNE STUBBE: How much?

  • AUDIENCE: Isn't it like 210 nanometers.

  • JOANNE STUBBE: I can't hear you.

  • You need to-- don't mumble.

  • Look at me in the face and tell me.

  • You know, don't be shy.

  • I mean, we all ask questions.

  • [INAUDIBLE]

  • We're here to learn.

  • Right?

  • Yeah?

  • AUDIENCE: It absorbs in the UV.

  • I think it's 210 nanometers.

  • JOANNE STUBBE: OK, so it's not 210.

  • So you guys need to go think about amino acids

  • and nucleic acid.

  • It absorbs at 260.

  • OK, so I mean, potentially, you could

  • sit at this absorption at 260.

  • But what does GTP look like?

  • GDP look like?

  • It has the same base.

  • So you're not going to see any change.

  • So that's useless because you need

  • to be able to monitor a change during the reaction.

  • OK, so what else about this molecule

  • will easily let you, as a chemist,

  • determine substrate from product?

  • AUDIENCE: The charge.

  • JOANNE STUBBE: Yeah, the charge, yes.

  • AUDIENCE: Just do anything with the charge.

  • JOANNE STUBBE: So here we have all of these negative--

  • every oxygen is negatively charged.

  • Here we only have two phosphates.

  • Every oxygen is negatively charged.

  • Phosphate-- all right, let me ask this question.

  • We'll see how much we need to be thinking about here.

  • So we have-- what is the charged state of phosphate?

  • Can anybody tell me?

  • AUDIENCE: Minus 3.

  • JOANNE STUBBE: Pardon me?

  • AUDIENCE: Minus 3.

  • It depends on the pH of your solution.

  • JOANNE STUBBE: Yeah, well, we're at neutral pH.

  • So you look at all the buffer.

  • You know what the buffers are.

  • They've described the buffer in their reaction.

  • So you're at neutral pH.

  • What is the charge?

  • AUDIENCE: Minus 2.

  • JOANNE STUBBE: Yeah, so it's the pKa of the first proton loss

  • is at 1.6.

  • And the pKa of the second proton loss is about 6.8.

  • So you'll have a mixture between 1 and 2.

  • So this is incredibly different from this.

  • And that makes it-- how do you separate things?

  • By an anion exchange column, which separates things

  • based on charge, some kind of a TLC system,

  • which can separate things based on charge.

  • And so that's what you have to do in your overall assay.

  • OK, so the second place where you're

  • going to use radioactivity is an assay.

  • OK, and in the paper you read, not only did they

  • use it for GTP, they had to use it to monitor peptide bond

  • formation.

  • Can anybody tell me how they did that?

  • So what are we looking at if we go back to the original?

  • What's the product of the reaction of the EF-Tu reaction

  • with the ribosome?

  • What's the product you get out?

  • AUDIENCE: [INAUDIBLE] on EF-Tu and also

  • label the hydrogen on leucine.

  • JOANNE STUBBE: OK, so you're labeling

  • the hydrogen on leucine.

  • OK, but then what are you looking at in your assay?

  • We're developing an assay.

  • Here we're developing an assay where

  • GTP is going to GDP plus Pi.

  • What are we looking at in the case of the leucine

  • in this experiment?

  • AUDIENCE: The leucine is incorporated into the peptide.

  • And you have the [INAUDIBLE].

  • JOANNE STUBBE: OK, so but where is the dipeptide?

  • So that's correct, yeah.

  • AUDIENCE: It will be in a P [INAUDIBLE] on the ribosome.

  • JOANNE STUBBE: Yeah, but what's it attached to?

  • Is it a dipeptide?

  • AUDIENCE: Yeah, it's attached to the less phenylalanine.

  • JOANNE STUBBE: Yeah, and what is that attached to?

  • AUDIENCE: Another tRNA.

  • JOANNE STUBBE: What's the phenylalanine attached to?

  • If you look over here, what is everything attached to?

  • AUDIENCE: Another tRNA.

  • JOANNE STUBBE: It's attached to a tRNA.

  • So could you separate a tRNA with one versus two amino acids

  • chemically?

  • Is that easy?

  • AUDIENCE: No.

  • JOANNE STUBBE: Now you have charges.

  • Right?

  • You have huge numbers of charges on your RNA.

  • But they're the same on all the tRNAs.

  • So you have one amino acid, which

  • has a carboxylate end and a second amino acid,

  • which has the same charge.

  • Do you think that's going to be easy to separate?

  • No.

  • So does anybody know what they did to make this assay work?

  • AUDIENCE: Put the label on leucine

  • so the leucine is incorporated.

  • Then you're still different [INAUDIBLE]..

  • You can have basic number.

  • Then after the conversion, you have a signal.

  • JOANNE STUBBE: OK, so after conversion, you have a signal.

  • But then the question is how do you detect this.

  • So you have--

  • I mean, I guess what they could have done-- so we started out

  • with a leucine that's labeled.

  • And so what you're saying is that you

  • have a way of detecting your leucine on the tRNA.

  • So this is all attached through an ester linkage.

  • So this is attached to the tRNA.

  • So what you would be after is separating an amino acid

  • from a tRNA.

  • So that's possible.

  • You could potentially do that.

  • But what do you think about the ester linkage?

  • This is all the thought process that goes into an assay

  • and making an assay robust.

  • Do you think that ester linkage is stable?

  • You're going to have to chromatograph it someway

  • to separate your starting material from product.

  • So the answer is it's not very stable.

  • And if you don't know, you've got to figure that out.

  • So what they do is they quench the reaction with hydroxide.

  • OK, and why did they quench the reaction with hydroxide?

  • So this is a rapid chemical quench

  • like we talked about last time.

  • Why did they do that?

  • AUDIENCE: To hydrolyze the ester.

  • JOANNE STUBBE: Exactly, so then what do you have?

  • You have, you know, your dipeptide here.

  • Or you could hydrolyze before.

  • And then you would have no label at all.

  • And so then you can monitor dipeptide formation.

  • So if you looked at the details of the graph

  • that they presented, they weren't

  • looking at tRNA charged with a dipeptide.

  • They were looking at the peptide.

  • And so that should have been a clue.

  • Immediately, you go back to understand

  • what's going on in the assay.

  • So you have assays.

  • This is pretty important.

  • And where's another place where you

  • might want to use radio label, where

  • you need a sensitive assay?

  • We're going to see radioactivity is incredibly sensitive.

  • I'm not getting very far.

  • But what other kind of an experiment

  • might you think about if you have

  • some kind of a mammalian cell, and you have receptors

  • on the cell, for example?

  • And you don't have very many receptors on the cell.

  • You have, you know, sub-nanomolar number

  • of receptors.

  • Where else might you want to use radioactivity?

  • And we're going to see this in the cholesterol section again.

  • Anybody got any idea?

  • So you have some receptor on a cell.

  • And you want to count the number of receptors.

  • We need a quantitative way of looking at that.

  • AUDIENCE: We need to measure uptake.

  • JOANNE STUBBE: So uptake is another place.

  • You absolutely would want to use it to measure uptake.

  • It's frequently used also to measure binding.

  • OK, so you have to figure out a way to prevent--

  • on the cell, you can prevent uptake by just cooling down

  • the lipids.

  • And then you're measuring binding.

  • OK, and that's exactly what they did in the LDL

  • where they count the number of LDL receptors.

  • So the other place where you're going

  • to see this used over and over again

  • is some kind of binding assay.

  • And there are many ways to measure binding.

  • You're going to have a whole recitation on this.

  • Most of them aren't as sensitive as the radioactive methodology.

  • OK, so let's move on after that long digression.

  • OK, so what you need then is a quantitative way

  • to measure radioactivity.

  • OK, oh, the other thing I wanted to just point out,

  • as you pointed out before, there's

  • another way of detecting radioactivity

  • using a phosphorimager.

  • And you can read about this in detail.

  • So what you do is you have your gel or a TLC plate.

  • You have an image plate on top of it

  • that somehow collects all the energy emitted

  • from your radioactive decay.

  • And then you quantitatively release that energy

  • in a way that allows you to quantitate

  • the amount of radioactivity you have

  • on your spot on the gel or your spot on the TLC plate.

  • And for example, tritium, with the lowest energy,

  • you might have to put a plate onto your gel

  • for a month and a half.

  • That's how insensitive it is.

  • You don't have enough energy to collect enough data to give you

  • some kind of an answer.

  • So you need to think about the energy,

  • and you need to think about the method of detection.

  • Tritium is the cheapest.

  • It's the easiest to get your hands on.

  • s it's the least sensitive because of the low energy

  • that's released.

  • OK, so the other thing that I think

  • is amazing about the phosphorimager is,

  • if you look at the linearity of detection,

  • it's linear over five or six orders of magnitude,

  • whereas, in the old days, you used to use some kind of film

  • on top.

  • And the film would absorb the radioactive decay

  • and make a spot.

  • And that was linear over a period

  • of over one order of magnitude.

  • So you had nonlinearity.

  • So that was really hard to do quantitation.

  • So phosphorimager have revolutionized

  • what you can do in terms of analyzing TLC or gels like Liz

  • talked about today in class.

  • OK, so what we need then is a quantitative way

  • of actually measuring radioactivity.

  • And what is the standard for radioactivity we use?

  • And so the quantitation and the standard is called a curie.

  • It also could be called becquerel

  • after the discovery of radioactivity.

  • And there's a relationship between the two.

  • And what we know, the standard of radioactivity with the Curie

  • is defined as the substance that decays at 3.7 times 10

  • to the 10th disintegrations per second.

  • So one curie equals 3.7 times 10 to the 10th disintegrations

  • per second.

  • Or the number that you often see is 2.2 times 10

  • to the 12th disintegrations per minute.

  • So this is often what you see on the bottles

  • when you actually buy radiolabeled material.

  • OK, so again, what you see is you're counting.

  • Efficiency, as I've already described,

  • varies with the energy that's released.

  • And you have to think about quenching.

  • That was just repeating what I've already told you.

  • OK, and so then what do you do?

  • So when you purchase radioactivity,

  • how does it come?

  • OK, so you guys are used to purchasing something from Sigma

  • or Aldrich or wherever you get it.

  • You look at it, and you can see something in the bottle.

  • When you purchase radioactivity, you can't see anything.

  • Why?

  • Because there's no material, almost no material

  • in your bottle.

  • It's all radioactivity.

  • So if you put it in a scintillation counter,

  • you would have, you know, 10 to the ninth decompositions

  • per minute, OK, but no material.

  • So you can't work with it because you can't weigh it.

  • You can't do anything with it.

  • OK, you have-- I don't know-- a picomole of material.

  • It depends on the material that you buy.

  • So the question is what do you do with this material

  • when you get it.

  • Well, you want to be able to use it.

  • And in our case, how are we using it?

  • We're going to buy GTP that's gamma P-32-labeled.

  • To be able to use this, we need to measure something.

  • So what is the first thing we do?

  • Has anybody got a guess?

  • You can't use what you buy because what you buy

  • is you'll get a little vial like this.

  • And that's what you see, or you might

  • be able to see some red material that's

  • decomposed material actually.

  • Yeah?

  • AUDIENCE: You need like a kinase that'll

  • exchange the phosphate with the radioactive phosphate.

  • JOANNE STUBBE: No, I mean, you could

  • do that if you wanted to convert it into something else.

  • But we want the gamma P-32-labeled ATP.

  • That's what we want to use in our assay.

  • So what do you do to make this usable?

  • AUDIENCE: You add some buffer.

  • JOANNE STUBBE: Do what?

  • AUDIENCE: You add some buffer to the [INAUDIBLE]..

  • JOANNE STUBBE: You add some buffer.

  • OK, does that change the amount of material?

  • No, so we probably do have some buffer, OK,

  • because we want to be able to transfer it into something

  • so we can do our assays.

  • So go ahead.

  • AUDIENCE: Yeah, then we're going to transfer it

  • when you have a specimen that you are going to take

  • some buffer [INAUDIBLE].

  • JOANNE STUBBE: OK, so you can, but you

  • have no material in there.

  • So if you had a substrate that was

  • 10 to the minus 12th molar in solution,

  • would the enzyme ever turn it over?

  • Probably not, because it could never find it.

  • OK, so that's not going to work.

  • So what is the-- go ahead.

  • What would you do?

  • AUDIENCE: Like would it matter if like

  • the radiolabeled phosphorus were just

  • like a fraction of regular phosphorus?

  • Like could you add some like unlabeled phosphorus?

  • JOANNE STUBBE: Exactly, and so this is the key point.

  • The first thing you do is you take unlabeled material,

  • and you add it into the radiolabeled material.

  • And how much you add depends on what you're using it for.

  • So if you're going to use assays,

  • and you don't need a very sensitive method,

  • you can add much more.

  • If you're going to look at a binding consent,

  • you know you're pushing a lower limit of detection

  • because you have some estimate of the number of receptors.

  • Then you would add much less.

  • So what you're going to do then-- the first thing

  • you do when you get radioactivity

  • is you add unlabeled material.

  • And I think this is something, if you didn't get anything

  • out else out of today's discussion,

  • I think most people won't get this.

  • When you work with radioactivity,

  • most of material, one molecule, only one molecule in 10

  • to the sixth to 10 to the ninth is radioactive.

  • All the rest are non-radioactive.

  • OK, so this is just telling you about the sensitivity

  • of the method.

  • Somehow using a scintillation counter

  • or using these phosphorimagers, you

  • can quantitate the amount of radioactivity you have present.

  • So when you're dealing with radio label, most of it

  • is unlabeled.

  • OK, so what does that tell you then?

  • So again, the amount of stuff is tiny.

  • When you add cold material, what does that allow you to do?

  • What that allows you to do is measure.

  • And this is the key take-home message.

  • Now you can measure the specific activity of your material.

  • OK, so you bought radiolabel.

  • Let's say tritium.

  • And then you added protonated material.

  • And the specific activity is the amount

  • of radioactivity per the amount of material

  • that you have present, the number of moles of material.

  • So it's in decompositions per minute per micromolar,

  • decompositions per nanomole.

  • And again, you have to change everything

  • to accommodate quenching effects.

  • So what you measure from a scintillation counter

  • is counts per minute, which is just decomposition

  • per minute times quenching.

  • So if there's 50%, you see half as much

  • as you should be seeing.

  • So specific activity is given in counts

  • per minute per amount, which is usually

  • in micromoles or nanomoles.

  • So if you know you have 1,000 counts per minute per nanomole,

  • and you count 100 counts, how many nanomoles do you have?

  • So you're given your specific activity.

  • You do an experiment.

  • You have 1,000 counts per minute per nanomole.

  • And when you count this-- whoops, when you count this,

  • you end up with 100 counts.

  • What amount of material do you have?

  • AUDIENCE: 21 moles.

  • JOANNE STUBBE: Yeah, so that's it.

  • So that's the quantitative relationship

  • you need to remember to do all these assays that are actually

  • in the paper that was described.

  • So let me just give you two examples of this.

  • We're already late.

  • But so this is tritium.

  • OK, does anybody see anything weird with tritiated cytidine.

  • So this was taken off of Google from Sigma.

  • You can buy this from Sigma now.

  • Do you think that's reasonable that we

  • CT3 in our methyl group?

  • So T is for tritium.

  • What did I just tell you about our material?

  • How much material has got a label in it?

  • How much--

  • AUDIENCE: One in 10 the the fourth.

  • JOANNE STUBBE: Yeah, so we don't have very much that's labeled.

  • Say we had 100% labeled.

  • Do you think that would be an issue?

  • Say we had a million to--

  • 10 to the sixth to 10 to the ninth more tritium.

  • What do you think that might do in terms of energy?

  • Yeah?

  • AUDIENCE: You said tritium is much weaker.

  • We're talking about phosphorus here.

  • So that's like a huge signal, whereas--

  • JOANNE STUBBE: So even with tritium,

  • OK, you still get enough energy.

  • If you tried to put that much tritium in your molecule,

  • within as fast as you could isolate the material,

  • it would be completely decomposed.

  • So there are ways to put tritium into the molecule,

  • but the decay would completely destroy your molecule

  • because you have so much radioactivity.

  • So this, which is on the web, is completely incorrect.

  • So what you have is one molecule in 10 to the sixth

  • that actually has tritium labeled.

  • And how much you have, you don't know.

  • What you need to do is add cold material,

  • and then you need to figure out a way

  • to quantitate the amount of material, leucine or GTP.

  • And then you count that amount of material.

  • And that gives you the specific activity.

  • So let me just say one more thing.

  • Those of you who have to go, I'm sorry I'm late.

  • You can go So where do you get radiolabeled material from?

  • Do you think this is easy?

  • I mean you could buy leucine.

  • I just showed you we could find that on the web.

  • You can buy a gamma P-32-labeled GTP as well.

  • Most things you can't buy.

  • OK, so this is what distinguishes a chemist

  • from a biologist in many cases because I could make things

  • radiolabeled decades ago.

  • Doing a 15-step synthesis, I was able to make molecules

  • that allowed me to study something

  • that nobody else could study.

  • So the question is you need to make your label

  • and put it in a specific position.

  • And so what do you start with?

  • You start with something that's easy to work with.

  • And you try to put the label in at the very end

  • of your synthesis.

  • And one of the things that you often start with

  • is sodium borotritiride.

  • Why would you start with sodium borotritiride?

  • What can sodium borohydride do?

  • This is frequently used.

  • We'll see this used later on.

  • Anybody remember what sodium borohydride does?

  • Yeah?

  • AUDIENCE: It's reductive.

  • JOANNE STUBBE: Yeah, it's a reductant.

  • So you can reduce a ketone or an aldehyde to an alcohol.

  • OK, so that's frequently used to put in tritium.

  • So what are the issues with sodium borohydride?

  • Again, this is something that you need

  • to think about the chemistry.

  • What are the issues with sodium borohydride?

  • If you're going to put your label in, OK, I just told you.

  • How much of your sodium borohydride is labeled?

  • What do you have mostly in there?

  • Do you have NaBT4?

  • No, so what do we know about tritium versus hydrogen?

  • I guess this might depend on how much organic chemistry you've

  • had.

  • Tritium versus hydrogen, what's the difference?

  • Two neutrons, OK, but it's huge in terms of weight,

  • OK, because neutrons are the same weight as the protons.

  • So what you see is an isotope effect on the reaction.

  • So when you use sodium borotritiride,

  • the activity is never the same as what

  • you got out of a bottle.

  • You have an isotope effect.

  • The other thing is, if any of you have ever worked with this,

  • and you're doing this in aqueous solution,

  • what does sodium borotritiride do?

  • Anybody got any ideas?

  • In water, at pH 7.

  • AUDIENCE: Proton exchange.

  • JOANNE STUBBE: Proton exchange.

  • AUDIENCE: You get hydrogen gas.

  • JOANNE STUBBE: You get hydrogen gas.

  • You get hydrogen gas.

  • The whole little flask would hit you in the face

  • with the hydrogen coming off when you're in--

  • and what would you get?

  • You'd get a face full of tritium, tritiated hydrogen.

  • OK, tritiated hydrogen is not so bad

  • because it's not very soluble.

  • So it goes into your system and gets washed out.

  • If you were producing tritiated water, that's bad.

  • So that's the other place where you do this.

  • You can get very hot labeled tritiated water.

  • And that you have to be really careful of because,

  • if you breathe that in, it gets mixed with all

  • the unlabeled materials.

  • And it takes forever to get rid of it.

  • So I think we're not even going to get to--

  • I'd let you go through all of this.

  • But what I want you to do now is go back and think

  • about what this data means.

  • At least you now know what the assays are.

  • And think about the axes.

  • And think about, you know, cognate versus near-cognate.

  • Why do we see a lag here?

  • What happens at 100%?

  • You're using up all the GTP.

  • What does that mean?

  • That's what I want you to think about.

  • If you come over here, and you're looking at dipeptide,

  • not tRNA.

  • We're looking at a dipeptide.

  • You need to look at the axes.

  • They're completely different.

  • One is micromole.

  • One is nanomole.

  • So we're trying to get you to actually look

  • at the primary data, which you may or may not--

  • how many saw this difference when you read the paper?

  • OK, so to me, this is what we're trying to get

  • you to do on the first test.

  • I can tell you a lot of people have trouble looking at this.

  • That's what we're trying to get you to do.

  • That's why we're going through this in so much detail.

  • And then it becomes second nature.

  • You just start reading it.

  • You look at the details.

  • And you make a judgment.

  • If you don't understand what's going on, you go look it up,

  • or you go talk to somebody about what

  • the issues are with the method.

  • Here again, the lag phases are not all that different.

  • But here, if you take the differences in amounts

  • into account, you're only getting 1%, 1% to 2% the amount

  • of leucine incorporated into the peptide

  • as you would with two phenylalanines.

  • And that's because it's a near-cognate.

  • And what's happening?

  • You know, you're having discrimination

  • between peptide bond formation and dissociation.

  • So that's the proofreading part of the overall mechanism.

  • So I think thinking about these two slides

  • really tells you quite a bit about whether you believe

  • the model that Rodnina--

  • whether the model is reasonable given the data

  • you actually see.

  • All right, I'm sorry.

  • I'm way over.

  • So I'm going to stop here.

The following content is provided under a Creative

字幕與單字

單字即點即查 點擊單字可以查詢單字解釋

B1 中級

R3.預穩態和穩態動力學方法在翻譯中的應用。 (R3. Pre-Steady State and Steady-State Kinetic Methods Applied to Translation)

  • 1 0
    林宜悉 發佈於 2021 年 01 月 14 日
影片單字